Nvidia-backed Iambic Therapeutics launches IPO in U.S. market

Key Facts

1Nvidia-backed biotech firm Iambic Therapeutics has launched its initial public offering (IPO) in the U.S. market.

Nvidia-backed biotech firm Iambic Therapeutics has launched its initial public offering (IPO) in the U.S. market. According to investing.com, the company, which utilizes artificial intelligence for drug discovery, has officially commenced its public listing process.

The move comes as the biotechnology sector shows resilience, with the company seeking to capitalize on Nvidia's expanding ecosystem in AI-driven healthcare. Regarding related market performance, NVDA closed at $237.47 on October 7, 2026, while AMD closed at $645.86 and INTC closed at $113.12 on the same date.